Vitroscope, a Trondheim, Norway-based biotechnology company developing platforms for live-tissue research, has secured $7 million in financing, comprising a $5 million seed round and $2 million in non-dilutive funding from the Research Council of Norway.
The seed round was co-led by Cerberus Ventures and YZR Capital, with participation from Arcas Ventures, Golden Egg Check and Devico Invest. Angel investors Carles Reina, Fàtima Godall and Oskari Pétas also participated.
The financing brings Vitroscope’s total funding to $8.8 million, according to the company.
Founded in 2019 by Carlo Kriesi and Heikki Sjöman, Vitroscope develops laboratory technology that allows researchers to study living human tissue under controlled conditions. Kriesi serves as CEO, while Sjöman is CTO. Sandra Jernström later joined as a co-founder and serves as Chief Business Development Officer.
The company focuses on perfusion technology, which maintains controlled fluid flow through biological samples. Its systems enable researchers to monitor tissue responses over time, including immune activity, treatment effects and disease mechanisms.
Vitroscope’s benchtop platform, vitro.alive, combines programmable perfusion with real-time monitoring of oxygen, pH and temperature. It also integrates live-cell imaging, allowing researchers to observe changes in biological samples during experiments.
The platform supports six independent experiments simultaneously and is compatible with standard inverted microscopes and existing tissue models.
Vitroscope is also developing vitro.scale, a higher-throughput system designed to support 96 parallel experiments. The company expects customer testing to begin in 2027, ahead of a planned commercial launch in 2028.
The newly secured funding will support the commercial rollout of vitro.alive and further validation of vitro.scale.
Vitroscope has also conducted research involving vascularized human brain organoids in collaboration with Instant Bio, maintaining the samples under perfusion for seven days. The company holds multiple international patents covering its underlying technology and methods.
